Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update

Artelo Biosciences, Inc. (NASDAQ:ARTL) saw a large decrease in short interest during the month of February. As of February 13th, there was short interest totaling 53,039 shares, a decrease of 52.0% from the January 29th total of 110,410 shares. Currently, 3.0% of the shares of the company are short sold. Based on an average daily trading volume, of 28,117 shares, the days-to-cover ratio is currently 1.9 days. Based on an average daily trading volume, of 28,117 shares, the days-to-cover ratio is currently 1.9 days. Currently, 3.0% of the shares of the company are short sold.

Artelo Biosciences Stock Up 2.5%

Shares of ARTL opened at $1.24 on Friday. Artelo Biosciences has a 52-week low of $1.10 and a 52-week high of $28.60. The company has a 50-day simple moving average of $1.47 and a 200-day simple moving average of $3.46. The company has a market capitalization of $2.63 million, a PE ratio of -0.06 and a beta of 1.13.

Wall Street Analyst Weigh In

ARTL has been the topic of a number of recent analyst reports. Maxim Group reiterated a “hold” rating on shares of Artelo Biosciences in a research note on Wednesday, November 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Artelo Biosciences in a research report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $24.00.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.